查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1856399

藥物研發外包市場按服務類型、藥物研發階段、工作流程、藥物類型、應用領域和最終用戶分類－2025-2032年全球預測

Drug Discovery Outsourcing Market by Service Type, Discovery Phase, Workflow, Drug Type, Application Area, End User - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 197 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，藥物研發外包市場規模將達到 77.1 億美元，複合年成長率為 8.65%。

關鍵市場統計數據
基準年 2024 39.6億美元
預計年份：2025年 42.9億美元
預測年份 2032 77.1億美元
複合年成長率 (%) 8.65%

技術整合、策略夥伴關係與營運韌性：重組後的藥物研發外包生態系統的背景介紹

全球藥物研發環境正經歷一場由技術突破、贊助商優先事項變化和經濟壓力轉變所驅動的劇變。外包已成為製藥和生技公司快速取得專業能力、管理研發風險、控制營運成本並縮短研發週期的核心策略手段，而這些專業能力往往是公司內部難以獲得的。那些兼具深厚生物學專業知識、合成化學能力和先進數據管理能力的外部供應商，正日益被視為轉化研究領域的合作夥伴，而不僅僅是供應商。

同時，機器學習、雲端原生資訊學和高內涵篩檢平台的興起正在改變人們對資料互通性和決策速度的期望。如今，申辦方更傾向於選擇能夠整合不同資料流、應用穩健的分析流程並將分析結果轉化為清晰的後續實驗步驟的合作夥伴。這種轉變有利於能夠將濕實驗室技術與計算工作流程結合的整合服務模式。此外，從重組生技藥品到精準小分子藥物，現代治療方法的複雜性也對那些展現出監管敏銳度和可擴展營運實踐的合約研究組織（CRO）和專業服務公司提出了更高的要求。

隨著企業在創新需求、日益嚴格的採購限制以及對供應鏈韌性的擔憂之間尋求平衡，外包選擇的關鍵在於靈活性、品質以及在探索階段之後開展合作開發專案的能力。摘要餘下部分概述了重塑外包策略的最重要因素，並為因應此變革環境的領導者提供了切實可行的指導。

人工智慧整合、自動化實驗室平台、模組化夥伴關係、供應鏈韌性和監管參與如何重塑外包策略

近年來，一系列變革性的變化正在重塑藥物研發外包的格局，並改變申辦方評估外部合作夥伴的方式。首先，人工智慧和進階分析技術融入先導化合物的篩選和最佳化流程，加速了假設的生成，實現了化合物庫的虛擬篩選，並優先進行能夠提供更高資訊價值的實驗。這種變化不僅體現在速度上，也意味著需要重新設計研發流程，使實驗更具針對性，並更有效地分配資源。

其次，實驗室自動化和檢測微型化並進，在提高通量的同時提升了可重複性。這項技術進步使服務供應商能夠提供可擴展的檢測連鎖，從而將更豐富、更標準化的資料輸入資訊平台。第三，業界正在採用模組化經營模式，將全方位服務的CRO合作關係與精品專家的合約結合，使申辦方能夠在不影響專案連續性的前提下，充分利用專業領域的專長。

第四，供應鏈韌性和地緣政治因素正迫使許多組織重新思考籌資策略，從而更加重視本地產能和單一來源風險規避。最後，監管機構在複雜療法和生物標記主導專案的研發討論中越來越早地介入，提高了外包商在方法論嚴謹性、可追溯性和合規性方面的要求。這些轉變正在形成一種格局，在這個格局中，能力深度、數據整合和策略契合度將決定長期夥伴關係關係的價值。

分析2025年美國關稅改革對供應鏈、採購慣例和外包業務連續性的多層次商業影響

2025年實施的政策變革和貿易措施為依賴跨境供應鏈獲取試劑、設備和中間體化合物的機構帶來了具體的營運考量。影響某些實驗室耗材、特殊化學品和特定設備零件的關稅調整增加了到岸成本，並導致關鍵投入品的前置作業時間出現波動。對於許多贊助商和研究機構而言，這直接促使他們重新評估採購計劃和供應商契約，以降低關稅波動和運輸中斷帶來的風險。

實際上，一些研發團隊已轉向雙重採購策略，以加快二級供應商的資格認證並維持實驗的連續性。另一些團隊則優先考慮與擁有本地庫存和區域製造能力的供應商合作，以減輕進口關稅和海關延誤的影響。有關價格轉嫁、不可抗力、交付服務水準協議等的合約條款已成為採購談判的重點，這反映出各方需要明確風險分配。

此外，營運團隊正在調整計劃進度，並在條件允許的情況下增加緩衝庫存，以應對間歇性延誤；財務和採購部門也在重新調整預算假設，以應對不斷上漲的可變投入成本。重要的是，關稅帶來的壓力正在強化現有的策略趨勢，即某些大批量或時間敏感型流程的區域化和近岸外包。

透過基於精細細分映射服務類型、發現階段、工作流程、藥物模式、治療應用和最終用戶動態的洞察，使供應商保持一致。

按服務類型進行細分，可以揭示贊助商在外包支出和預期方面的關注重點。根據服務類型，市場可分為生物服務、化學服務和資料管理服務三大類。生物服務進一步細分為檢測方法開發和生物測試，反映了對穩健、可轉化檢測方法以及體外/體內測試能力的需求。化學服務進一步細分為客製化合成和製程研發，凸顯了對客製化化學解決方案和可擴展路線開發的持續需求。資料管理服務進一步細分為生物資訊學和資料整合，強調了整合多體學和篩檢資料的能力已成為服務提供者的競爭優勢。

藥物發現階段的細分突顯了專案推進過程中專業知識最為關鍵的領域。根據藥物發現階段，市場探索涵蓋先導化合物最佳化和標靶識別。先導化合物包括化合物篩檢和基於結構的藥物設計，重點在於迭代化學類型最佳化和計算選擇。標靶辨識則進一步涵蓋生物標記發現和基因組定序方法，體現了對分子表徵和患者分層方法的投入。

以工作流程為中心的細分將能力與專案里程碑相對應。基於工作流程，市場被分類為先導化合物識別和候選藥物最佳化、臨床前開發、目標化合物識別和篩檢、目標化合物驗證以及功能資訊學，從而幫助申辦方將供應商​​的技能與計劃階段相匹配。先導化合物類型細分則突顯了特定療法的需求。根據藥物類型，市場被分為大分子和小分子藥物。大分子藥物進一步細分為生物製藥和生物相似藥，突顯了分析需求和生產路徑的差異。應用細分將治療重點與技術需求相匹配。根據應用領域，市場被分為心血管疾病、感染疾病和癌症。心血管疾病進一步細分為心臟衰竭和高血壓。感染疾病進一步細分為細菌感染和病毒感染。腫瘤學進一步細分為血液系統惡性腫瘤和固態腫瘤，突顯了對疾病特異性檢測套件的需求。最終用戶細分揭示了通路動態和決策促進因素。根據最終用戶，市場研究涵蓋合約研究組織 (CRO)、製藥和生物技術公司以及研究機構。 CRO 又進一步細分為全方位服務 CRO 和專業 CRO。製藥和生物技術公司則進一步細分為大型企業和小型企業。研究受託研究機構則進一步細分為學術機構和政府研究中心，這些機構會影響採購週期和合作研究獎勵。

這些細分視角提供了一種精細的方法來評估提供者是否符合各個項目的要求，使贊助商能夠將服務範圍、技術深度和監管一致性與計劃的具體階段和治療重點相匹配。

深入分析美洲、歐洲、中東和非洲以及亞太地區各自如何影響外包合作夥伴的選擇和業務策略。

不同地區的策略外包選擇受不同的促進因素和阻礙因素影響。在美洲，生物技術創新中心和創投支援的項目集中在尋求快速且靈活的夥伴關係模式，這持續推動對整合式發現服務和先進數據分析能力的強勁需求。在此背景下，擁有深厚的治療領域專業知識、強大的數據平台以及熟悉監管機構的供應商正成為快速發展計畫的首選合作夥伴。

歐洲、中東和非洲呈現出異質性格局，統一的監管環境和專業轉化中心為跨境合作提供了支持，但西方國家和新興市場在區域能力和人才儲備方面存在顯著差異。在該地區營運的贊助商強調嚴格的合規制度和生物樣本來源，致力於建立連接學術創新和產業發展的合作體系。

亞太地區正迅速發展成為卓越的科學中心，並提供具成本效益的實驗室服務，尤其是在生技藥品、合成化學和高通量篩檢。對區域生產能力和區域監管路徑的投資正在減少後期臨床前試驗中需要規模化和快速推進的項目所面臨的阻力。在所有地區，本地能力、監管預期和供應鏈韌性之間的相互作用都體現在合作夥伴的選擇和合約模式中。

關鍵的企業層面動態表明，整合平台、專業夥伴關係和卓越的合規性如何驅動競爭差異化和客戶偏好。

企業級競爭力日益取決於整合跨學科能力並維持高品質標準和合規性的能力。大型委外研發機構和專業供應商透過投資專有平台、與科技公司建立策略聯盟以及在小分子和生技藥品專案方面累積的豐富經驗來脫穎而出。擁有嵌入式運算團隊和檢驗的生物資訊流程的公司能夠提供更具預測性的決策支援並縮短迭代周期。

夥伴關係模式至關重要。能夠管理端到端藥物研發流程的全方位服務供應商對尋求專案連續性的申辦者仍然具有吸引力，而專業CRO在複雜檢測、客製化化學方法和新型療法方面擁有專業知識，因此必不可少。大型整合商與細分領域專家之間的合作是一種常見模式，大型公司負責協調專案交付，而專業公司則提供關鍵的技術深度。此外，那些重視透明的品質系統、可追溯的資料管理實務和清晰的監管文件的公司，在支持轉化醫學和生物標記主導專案時，具有競爭優勢。

平台授權、地理擴張以及對本地製造和試劑供應鏈的共同投資等策略性舉措，是企業滿足客戶需求的切實可行的方法。最終，供應商的選擇取決於服務廣度、技術能力深度以及將專案風險和進度與商業條款相匹配的能力之間的權衡。

領導者可以採取指南來最佳化供應商的韌性、資料互通性、合約靈活性、監管一致性和技術資格合格

產業領導者可以採取以下幾個切實可行的步驟來增強其外包能力，並從外部夥伴關係中獲得更大價值。首先，透過對多家供應商進行關鍵能力認證，並制定應急計畫以降低單一來源風險，從而實現供應商生態系統的多元化。這種方法既能提高韌性，又不會影響對專業方法的取得。其次，投資於可互通的資料標準和安全的雲端架構，以實現委託方和外部實驗室之間的無縫交接。

第三，採用靈活的合約框架，使各階段的獎勵保持一致，並允許隨著科學假設的演進調整專案範圍。此類模式可以包括分階段簽訂的契約，並明確啟動/終止標準，以及預先協商的規模化方案。第四，為最大限度地降低下游合規風險，優先選擇在複雜模式和生物標記主導試驗方面擁有豐富監管經驗的供應商。第五，為降低關稅和物流風險，考慮制定區域產能策略，將區域庫存管理與全球戰略合作夥伴結合。

最後，要建立內部快速技術評估和供應商資格資格確認，包括建立結構化的評分卡，用於評估科學嚴謹性、資料管治、品質系統和成本透明度。透過將營運規範與策略夥伴關係設計結合，企業可以將外包從一項交易性支出轉變為一種競爭優勢，在控制風險的同時加速探索進程。

採用嚴謹的混合方法研究途徑，結合高階主管訪談、二手技術審查、能力映射和情境分析，以產生可操作的情報。

本摘要的研究結合了定性和定量方法，以確保得出可靠且可驗證的結論。主要研究包括對贊助公司和服務供應商的研發主管、採購負責人和技術總監進行結構化訪談，以獲取有關能力需求、供應商選擇標準和區域營運限制的第一手觀點。此外，也諮詢了監管專家和供應鏈專業人士，以了解政策和物流的影響。

二次研究整合了已發表的科學文獻、監管指南、公司揭露資訊、專利概況和技術白皮書，以識別檢測平台、計算實現和特定模式研發方法的發展趨勢。數據綜合強調跨多個來源的檢驗，以最大限度地減少偏差，並確保結論反映的是多方面的證據，而非單一來源的假設。

分析方法包括根據細分框架進行能力映射和情境分析，以探討關稅、供應中斷和技術應用如何改變風險狀況。調查方法優先考慮假設的透明度，並採用迭代專家評審週期來完善解釋和建議。始終關注相關人員可應用於籌資策略、夥伴關係設計和產業計畫的可操作性見解。

簡明扼要的結論強調了藥物研發外包專案成功的關鍵在於科學嚴謹性、整合資料系統和策略風險管理。

摘要：藥物研發外包領域正日益成熟，逐漸發展成為一個更加一體化、數據主導的生態系統，其中戰略夥伴關係的選擇對專案進度和科研成果有著顯著影響。計算化學、自動化檢測系統和數據整合技術的進步，使得能夠提供可重複、可解釋的資料集，並將這些結果轉化為明確的後續實驗步驟的供應商變得愈發重要。

同時，政策發展和供應鏈壓力凸顯了多元化籌資策略和區域營運計畫的必要性。積極主動篩選替代供應商、最佳化庫存策略並協商靈活的合約條款的贊助商，即使在外部干擾時期，也能更好地保持研發勢頭。公司差異化優勢將體現在其能否將深厚的技術專長與透明的品質和資料管治實務結合，從而支持監管溝通和專案擴充性。

歸根究底，當今時代成功的商業外包需要科學嚴謹性、技術整合和切實可行的風險管理三者之間的平衡。能夠使其合作夥伴生態系統與這些原則保持一致的組織，可以加快探索速度，減少不必要的延誤，並建立從假設到候選方案篩選更可預測的路徑。

目錄

第1章：序言

第2章調查方法

第3章執行摘要

第4章 市場概覽

第5章 市場洞察

  • 在藥物發現外包服務中採用人工智慧主導的目標識別和先導藥物最適化平台
  • 將高內涵成像和微流體篩檢技術整合到CRO的檢測開發平臺中
  • 一個不斷發展的受託製造廠商，專門從事單株抗體和生技藥品的規模化生產服務。
  • 生物技術公司擴大透過與專業合約研究組織（CRO）合作來使用CRISPR基因編輯服務。
  • 製藥公司與外包服務供應商之間雲端基礎的虛擬篩檢和In Silico模擬合作正在蓬勃發展。
  • 新興的整合數位雙胞胎平台用於最佳化製造外包中的生物製程開發
  • 監管協調工作旨在促進臨床前和臨床藥物發現服務的跨境外包
  • 對用於化合物合成和製程開發外包的永續綠色化學平台的需求日益成長
  • 夥伴關係模式，旨在加速小眾療法的發現。
  • 由專業供應商提供的客製化患者來源類器官和iPSC模型，用於精準腫瘤學外包

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章：按服務類型分類的藥物研發外包市場

  • 生物服務
    • 檢測方法開發
    • 生物學檢測
  • 化學服務
    • 客製合成
    • 製程研究與開發
  • 資料管理服務
    • 生物資訊學
    • 資料整合

9. 依藥物發現階段分類的藥物發現外包市場

  • 先導藥物最適化
    • 化合物篩檢
    • 基於結構的藥物設計
  • 目標識別
    • 生物標記發現
    • 基因組定序

第10章：依工作流程分類的藥物研發外包市場

  • 先導化合物發現及候選化合物最佳化
  • 臨床前開發
  • 目標識別與篩檢
  • 目標驗證與功能資訊學

第11章：以藥物類型分類的藥物研發外包市場

  • 大分子
    • 生技藥品
    • 生物相似藥
  • 低分子

第12章 依應用領域分類的藥物研發外包市場

  • 心血管疾病
    • 心臟衰竭
    • 高血壓
  • 感染疾病
    • 細菌感染疾病
    • 病毒感染疾病
  • 腫瘤學
    • 骨髓惡性腫瘤
    • 固態腫瘤

第13章：以最終用戶分類的藥物研發外包市場

  • 受託研究機構
    • 全方位CRO服務
    • 專業合約研究組織
  • 製藥和生物技術公司
    • 主要企業
    • 小型企業
  • 研究所
    • 學術機構
    • 政府研究中心

第14章 各地區藥物研發外包市場

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第15章 藥物研發外包市場（依群體分類）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第16章 各國藥物研發外包市場

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第17章 競爭格局

  • 2024年市佔率分析
  • FPNV定位矩陣，2024
  • 競爭分析
    • Agilent Technologies Inc.
    • Aragen Life Sciences Ltd.
    • BPS Bioscience, Inc.
    • Celentyx Ltd.
    • Charles River Laboratories International, Inc.
    • Covance, Inc.
    • Crown Bioscience, Inc.
    • Curia Global, Inc.
    • Dalton Pharma Services
    • Eurofins Scientific
    • Evotec SE
    • Explicyte
    • GenScript Biotech Corporation
    • HD Biosciences Co., Ltd.
    • IQVIA
    • Jubilant Biosys Ltd.
    • Laboratory Corporation of America Holdings
    • Merck & Co., Inc.
    • Oncodesign Services
    • Personalis, Inc.
    • Pfizer Inc.
    • PPD Inc.
    • Promega Corporation
    • Revvity Discovery Limited
    • Sanofi SA
    • STC Biologics Inc.
    • Syngene International Ltd.
    • TCG Lifesciences Pvt. Limited
    • Thermo Fisher Scientific Inc.
    • WuXi AppTec Co., Ltd.
Product Code: MRR-742BD517D92E

The Drug Discovery Outsourcing Market is projected to grow by USD 7.71 billion at a CAGR of 8.65% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 3.96 billion
Estimated Year [2025] USD 4.29 billion
Forecast Year [2032] USD 7.71 billion
CAGR (%) 8.65%

Contextual introduction to the reshaped drug discovery outsourcing ecosystem shaped by technology convergence, strategic partnerships, and operational resilience

The global drug discovery environment is undergoing a period of structural change driven by technological breakthroughs, evolving sponsor priorities, and shifting economic pressures. Outsourcing has become a core strategic lever for pharmaceutical and biotechnology organizations to access specialized capabilities rapidly, manage development risk, and control operational costs while accelerating timelines through expertise not readily available in-house. External providers that combine deep biological expertise, synthetic chemistry capabilities, and advanced data management are increasingly viewed as partners in translational research rather than simple vendors.

Concurrently, the rise of machine learning, cloud-native informatics, and high-content screening platforms has altered expectations around data interoperability and decision velocity. Sponsors now prioritize partners who can ingest heterogeneous data streams, apply robust analytic pipelines, and translate outputs into clear experimental next steps. This shift favors integrated service models that bridge wet-lab proficiency with computational workflows. Moreover, the complexity of modern modalities-ranging from engineered biologics to precision small molecules-places a premium on CROs and specialty service firms that demonstrate regulatory acumen and scalable operational practices.

As organizations balance the need for innovation with tighter procurement scrutiny and supply chain resilience concerns, outsourcing choices hinge on flexibility, quality, and the ability to co-develop programs across discovery phases. The remainder of this summary outlines the most consequential forces reshaping outsourcing strategies and offers pragmatic guidance for leaders navigating this transformed environment.

How AI integration, automated laboratory platforms, modular partnering, supply chain resilience, and regulatory engagement are reshaping outsourcing strategies

Recent years have seen a series of transformative shifts that are redefining the contours of drug discovery outsourcing and changing how sponsors evaluate external partners. First, the integration of AI and advanced analytics into lead identification and optimization workflows is accelerating hypothesis generation, enabling virtual triage of compound libraries and prioritizing experiments that yield higher informational value. This change is not merely about speed; it is about altering the design of discovery programs so that experiments are more targeted and resource allocation is more efficient.

Second, the parallel advancement of laboratory automation and miniaturized assays has expanded throughput while improving reproducibility. This technological progression allows service providers to offer scalable assay cascades that feed richer, more standardized data into informatics platforms. Third, the industry has embraced modular business models in which sponsors combine full-service CRO relationships with boutique specialist engagements to access niche capabilities without sacrificing program continuity.

Fourth, supply chain resiliency and geopolitical factors have prompted many organizations to reconsider sourcing strategies, resulting in increased interest in regional capacity and single-source risk mitigation. Finally, regulatory authorities are engaging earlier in development conversations around complex modalities and biomarker-driven programs, which raises the bar for outsourced partners to demonstrate methodological rigor, traceability, and compliance. Together, these shifts are producing a landscape where capability depth, data integration, and strategic alignment determine long-term partnership value.

Analyzing the layered operational consequences of the United States tariff changes in 2025 on supply chains, procurement practices, and outsourcing continuity

Policy changes and trade measures introduced in 2025 have introduced tangible operational considerations for organizations that rely on cross-border supply chains for reagents, instrumentation, and intermediate compounds. Tariff adjustments affecting certain classes of laboratory consumables, specialized chemicals, and selected instrumentation components have increased landed costs and introduced variability in lead times for critical inputs. For many sponsors and providers, the immediate consequence has been a re-evaluation of sourcing maps and vendor contracts to reduce exposure to tariff volatility and shipping disruptions.

In practical terms, some discovery groups have accelerated qualification of secondary suppliers and moved to dual-sourcing strategies to maintain experimental continuity. Others have prioritized vendor partnerships that include local inventory stocking or regional manufacturing capabilities to limit the impact of import duties and customs delays. Contractual clauses related to price pass-through, force majeure, and delivery SLAs have become focal points during procurement negotiations, reflecting the need to allocate risk explicitly.

Operational teams are also adjusting project timelines and buffer inventories where possible to accommodate intermittent delays, while finance and procurement functions are recalibrating budgeting assumptions to account for higher variable input costs. Importantly, the tariff-driven pressures are reinforcing pre-existing strategic trends toward regionalization and nearshoring for certain high-volume or time-sensitive processes, without necessarily undoing the advantages of global capability networks that are required for specialized technologies and rare expertise.

Granular segmentation-driven insights that map service types, discovery phases, workflows, drug modalities, therapeutic applications, and end-user dynamics for vendor alignment

Service-type segmentation reveals where sponsors are concentrating their outsourcing spend and expectations. Based on Service Type, the market is studied across Biological Services, Chemical Services, and Data Management Services. The Biological Services is further studied across Assay Development and Biological Testing, reflecting demand for robust, translatable assays and in vitro/in vivo testing capacities. The Chemical Services is further studied across Custom Synthesis and Process R&D, highlighting the continued need for bespoke chemistry solutions and scalable route development. The Data Management Services is further studied across Bioinformatics and Data Integration, underscoring that the ability to harmonize multi-omic and screening data is now a competitive differentiator for providers.

Discovery-phase segmentation clarifies where specialized competencies matter most during program progression. Based on Discovery Phase, the market is studied across Lead Optimization and Target Identification. The Lead Optimization is further studied across Compound Screening and Structure-Based Drug Design, indicating a focus on iterative chemotype refinement and computationally guided selection. The Target Identification is further studied across Biomarker Discovery and Genomic Sequencing Methods, reflecting investments in molecular characterization and patient-stratified approaches.

Workflow-focused segmentation maps capabilities to program milestones. Based on Workflow, the market is studied across Lead Identification & Candidate Optimization, Preclinical Development, Target Identification & Screening, and Target Validation & Functional Informatics, which helps sponsors align provider skill sets to project phases. Drug-type segmentation separates modality-specific requirements. Based on Drug Type, the market is studied across Large Molecules and Small Molecules. The Large Molecules is further studied across Biologics and Biosimilar, indicating divergence in analytical demands and manufacturing pathways. Application-area segmentation aligns therapeutic focus with technical needs. Based on Application Area, the market is studied across Cardiovascular Diseases, Infectious Diseases, and Oncology. The Cardiovascular Diseases is further studied across Heart Failure and Hypertension. The Infectious Diseases is further studied across Bacterial Infections and Viral Infections. The Oncology is further studied across Hematological Malignancies and Solid Tumors, emphasizing the need for disease-specific assay suites. End-user segmentation clarifies channel dynamics and decision drivers. Based on End User, market is studied across Contract Research Organizations, Pharmaceutical & Biotechnology Companies, and Research Institutes. The Contract Research Organizations is further studied across Full-Service CROs and Specialty CROs. The Pharmaceutical & Biotechnology Companies is further studied across Large Enterprises and SMEs. The Research Institutes is further studied across Academic Institutions and Government Research Centers, which affects procurement cycles and collaboration incentives.

These segmentation lenses collectively provide a granular way to evaluate provider fit for discrete program requirements, enabling sponsors to match service scope, technological depth, and regulatory alignment to the specific stage and therapeutic focus of their projects.

Regional intelligence on how Americas, Europe Middle East & Africa, and Asia-Pacific each distinctively influence outsourcing partner selection and operational strategies

Regional dynamics are shaping strategic choices for outsourcing, with distinct drivers and constraints in each geography. Americas continue to exhibit strong demand for integrated discovery services and advanced data analytics capabilities, driven by a concentration of biotech innovation hubs and venture-backed programs that demand speed and flexible partnership models. In this context, providers that combine deep therapeutic expertise with robust data platforms and regulatory familiarity tend to be preferred partners for fast-moving development programs.

Europe, Middle East & Africa presents a heterogeneous landscape where regulatory harmonization and access to specialized translational centers support collaboration across borders, while localized capacity and talent pools differ markedly between Western and emerging markets. Sponsors operating in this region emphasize rigorous compliance frameworks and provenance for biological materials, along with collaborative arrangements that bridge academic innovation and industrial development.

Asia-Pacific remains a focal point for both cost-efficient laboratory services and rapidly maturing centers of scientific excellence, particularly in biologics, synthetic chemistry, and high-throughput screening. Investments in regional manufacturing capacity and local regulatory pathways are reducing friction for programs that require scale and speed in late-stage preclinical work. Across all regions, the interplay between local capabilities, regulatory expectations, and supply chain resilience informs partner selection and contracting models.

Key company-level dynamics showing how integrated platforms, specialist partnerships, and compliance excellence determine competitive differentiation and client preference

Company-level competitive dynamics are increasingly defined by the ability to integrate cross-disciplinary capabilities while maintaining high standards of quality and compliance. Leading contract research organizations and specialty providers differentiate themselves through investments in proprietary platforms, strategic alliances with technology firms, and demonstrated experience across both small molecule and biologics programs. Firms with embedded computational teams and validated bioinformatics pipelines are able to offer more predictive decision support and shorter iteration cycles.

Partnership models matter: full-service providers that can manage end-to-end discovery workflows retain appeal for sponsors seeking program continuity, whereas specialty CROs remain essential for complex assays, custom chemistry, and novel modality expertise. Collaboration between larger integrators and niche specialists is a common pattern, where the larger firm coordinates program delivery while the specialist contributes critical technical depth. Additionally, companies that emphasize transparent quality systems, traceable data management practices, and clear regulatory documentation have a competitive advantage when supporting translational or biomarker-driven programs.

Strategic moves such as platform licensing, geographic expansion, and co-investment in localized manufacturing or reagent supply chains are practical ways companies are responding to client needs. Ultimately, vendor selection reflects a trade-off between breadth of services, depth of technical competence, and the ability to align commercial terms to program risk and timelines.

Actionable recommendations for leaders to optimize supplier resilience, data interoperability, contracting flexibility, regulatory alignment, and technology qualification

Industry leaders can take several pragmatic steps to strengthen their outsourcing posture and extract greater value from external partnerships. First, diversify supplier ecosystems by qualifying multiple providers for critical capabilities and establishing contingency plans that reduce single-source exposure. This approach improves resilience without sacrificing access to specialized methods. Second, invest in interoperable data standards and secure cloud architectures that allow seamless handoffs between sponsors and external laboratories, thereby reducing rework and accelerating decision-making.

Third, adopt flexible contracting frameworks that align incentives across milestones and allow scope adjustments as scientific hypotheses evolve. Such models can include phased engagements with clear go/no-go criteria and pre-negotiated options for scale-up. Fourth, prioritize vendors with demonstrated regulatory experience in complex modalities and biomarker-driven trials to minimize downstream compliance risk. Fifth, consider regional capacity strategies that combine local inventory control with strategic global partners to mitigate tariff and logistics exposure.

Finally, cultivate internal capabilities for rapid technology assessment and vendor qualification, including structured scorecards that evaluate scientific rigor, data governance, quality systems, and cost transparency. By combining operational discipline with strategic partnership design, organizations can convert outsourcing from a transactional expense into a competitive advantage that accelerates discovery while managing risk.

Rigorous mixed-methods research approach combining executive interviews, secondary technical review, capability mapping, and scenario analysis to produce actionable intelligence

The research underpinning this summary combined qualitative and quantitative approaches to ensure robust, defensible insights. Primary research included structured interviews with senior R&D executives, procurement leaders, and technical heads across sponsor organizations and service providers to capture first-hand perspectives on capability requirements, vendor selection criteria, and regional operational constraints. These interviews were complemented by expert consultations with regulatory affairs professionals and supply chain specialists to contextualize policy and logistics impacts.

Secondary research incorporated published scientific literature, regulatory guidance, company disclosures, patent landscapes, and technology white papers to triangulate trends in assay platforms, computational adoption, and modality-specific development practices. Data synthesis emphasized validation across multiple sources to minimize bias and ensure that conclusions reflect convergent evidence rather than single-source assumptions.

Analytical methods included capability mapping against the segmentation schema and scenario analysis to explore how tariffs, supply disruptions, and technological adoption alter risk profiles. The methodology prioritized transparency in assumptions and used iterative review cycles with domain experts to refine interpretation and recommendations. Throughout, emphasis was placed on actionable insights that stakeholders can apply to procurement strategy, partnership design, and operational planning.

Concise conclusion emphasizing the necessity of scientific rigor, integrated data systems, and strategic risk management for successful outsourced discovery programs

In summary, the drug discovery outsourcing landscape is maturing into a more integrated, data-driven ecosystem where strategic partnership choices materially affect program velocity and scientific outcomes. Advances in computational chemistry, automated assay systems, and data integration technologies are elevating the importance of providers that can deliver reproducible, interpretable datasets and translate those outputs into defined experimental next steps.

Concurrently, policy developments and supply chain pressures have highlighted the need for diversified sourcing strategies and regional operational planning. Sponsors that proactively qualify alternative suppliers, rationalize inventory strategies, and negotiate adaptive contracting terms will be better positioned to sustain discovery momentum during periods of external disruption. Company differentiation is rooted in the capacity to combine deep technical expertise with transparent quality and data governance practices that support regulatory engagement and program scalability.

Ultimately, successful outsourcing in the current era requires a balance of scientific rigor, technological integration, and pragmatic risk management. Organizations that align their partner ecosystem to these principles can accelerate discovery, reduce avoidable delays, and create more predictable pathways from hypothesis to candidate selection.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Adoption of AI-driven target identification and lead optimization platforms in outsourced drug discovery services
  • 5.2. Integration of high-content imaging and microfluidic screening technologies in CRO assay development pipelines
  • 5.3. Expansion of contract manufacturing organizations specializing in monoclonal antibody and biologics scale-up services
  • 5.4. Increased utilization of CRISPR gene editing services by biotech companies through specialized CRO partnerships
  • 5.5. Surge in cloud-based virtual screening and in silico modeling collaborations between pharma and outsourcing providers
  • 5.6. Emergence of integrated digital twin platforms to optimize bioprocess development in outsourced manufacturing
  • 5.7. Regulatory harmonization efforts facilitating cross-border outsourcing of preclinical and clinical drug discovery services
  • 5.8. Rising demand for sustainable green chemistry platforms in outsourced compound synthesis and process development
  • 5.9. Partnership models combining small biotech firms with global CRO networks to accelerate niche therapeutic discovery
  • 5.10. Customization of patient-derived organoid and iPSC models by specialized vendors for precision oncology outsourcing

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Drug Discovery Outsourcing Market, by Service Type

  • 8.1. Biological Services
    • 8.1.1. Assay Development
    • 8.1.2. Biological Testing
  • 8.2. Chemical Services
    • 8.2.1. Custom Synthesis
    • 8.2.2. Process R&D
  • 8.3. Data Management Services
    • 8.3.1. Bioinformatics
    • 8.3.2. Data Integration

9. Drug Discovery Outsourcing Market, by Discovery Phase

  • 9.1. Lead Optimization
    • 9.1.1. Compound Screening
    • 9.1.2. Structure-Based Drug Design
  • 9.2. Target Identification
    • 9.2.1. Biomarker Discovery
    • 9.2.2. Genomic Sequencing Methods

10. Drug Discovery Outsourcing Market, by Workflow

  • 10.1. Lead Identification & Candidate Optimization
  • 10.2. Preclinical Development
  • 10.3. Target Identification & Screening
  • 10.4. Target Validation & Functional Informatics

11. Drug Discovery Outsourcing Market, by Drug Type

  • 11.1. Large Molecules
    • 11.1.1. Biologics
    • 11.1.2. Biosimillar
  • 11.2. Small Molecules

12. Drug Discovery Outsourcing Market, by Application Area

  • 12.1. Cardiovascular Diseases
    • 12.1.1. Heart Failure
    • 12.1.2. Hypertension
  • 12.2. Infectious Diseases
    • 12.2.1. Bacterial Infections
    • 12.2.2. Viral Infections
  • 12.3. Oncology
    • 12.3.1. Hematological Malignancies
    • 12.3.2. Solid Tumors

13. Drug Discovery Outsourcing Market, by End User

  • 13.1. Contract Research Organizations
    • 13.1.1. Full-Service CROs
    • 13.1.2. Specialty CROs
  • 13.2. Pharmaceutical & Biotechnology Companies
    • 13.2.1. Large Enterprises
    • 13.2.2. SMEs
  • 13.3. Research Institutes
    • 13.3.1. Academic Institutions
    • 13.3.2. Government Research Centers

14. Drug Discovery Outsourcing Market, by Region

  • 14.1. Americas
    • 14.1.1. North America
    • 14.1.2. Latin America
  • 14.2. Europe, Middle East & Africa
    • 14.2.1. Europe
    • 14.2.2. Middle East
    • 14.2.3. Africa
  • 14.3. Asia-Pacific

15. Drug Discovery Outsourcing Market, by Group

  • 15.1. ASEAN
  • 15.2. GCC
  • 15.3. European Union
  • 15.4. BRICS
  • 15.5. G7
  • 15.6. NATO

16. Drug Discovery Outsourcing Market, by Country

  • 16.1. United States
  • 16.2. Canada
  • 16.3. Mexico
  • 16.4. Brazil
  • 16.5. United Kingdom
  • 16.6. Germany
  • 16.7. France
  • 16.8. Russia
  • 16.9. Italy
  • 16.10. Spain
  • 16.11. China
  • 16.12. India
  • 16.13. Japan
  • 16.14. Australia
  • 16.15. South Korea

17. Competitive Landscape

  • 17.1. Market Share Analysis, 2024
  • 17.2. FPNV Positioning Matrix, 2024
  • 17.3. Competitive Analysis
    • 17.3.1. Agilent Technologies Inc.
    • 17.3.2. Aragen Life Sciences Ltd.
    • 17.3.3. BPS Bioscience, Inc.
    • 17.3.4. Celentyx Ltd.
    • 17.3.5. Charles River Laboratories International, Inc.
    • 17.3.6. Covance, Inc.
    • 17.3.7. Crown Bioscience, Inc.
    • 17.3.8. Curia Global, Inc.
    • 17.3.9. Dalton Pharma Services
    • 17.3.10. Eurofins Scientific
    • 17.3.11. Evotec SE
    • 17.3.12. Explicyte
    • 17.3.13. GenScript Biotech Corporation
    • 17.3.14. HD Biosciences Co., Ltd.
    • 17.3.15. IQVIA
    • 17.3.16. Jubilant Biosys Ltd.
    • 17.3.17. Laboratory Corporation of America Holdings
    • 17.3.18. Merck & Co., Inc.
    • 17.3.19. Oncodesign Services
    • 17.3.20. Personalis, Inc.
    • 17.3.21. Pfizer Inc.
    • 17.3.22. PPD Inc.
    • 17.3.23. Promega Corporation
    • 17.3.24. Revvity Discovery Limited
    • 17.3.25. Sanofi S.A.
    • 17.3.26. STC Biologics Inc.
    • 17.3.27. Syngene International Ltd.
    • 17.3.28. TCG Lifesciences Pvt. Limited
    • 17.3.29. Thermo Fisher Scientific Inc.
    • 17.3.30. WuXi AppTec Co., Ltd.

LIST OF FIGURES

  • FIGURE 1. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY SERVICE TYPE, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY SERVICE TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY DISCOVERY PHASE, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY DISCOVERY PHASE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY WORKFLOW, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY WORKFLOW, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY DRUG TYPE, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY DRUG TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY APPLICATION AREA, 2024 VS 2032 (%)
  • FIGURE 11. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY APPLICATION AREA, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY END USER, 2024 VS 2032 (%)
  • FIGURE 13. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. AMERICAS DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. NORTH AMERICA DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. LATIN AMERICA DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. EUROPE, MIDDLE EAST & AFRICA DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. EUROPE DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. MIDDLE EAST DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. AFRICA DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. ASIA-PACIFIC DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. ASEAN DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. GCC DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. EUROPEAN UNION DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. BRICS DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 28. G7 DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 29. NATO DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 30. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 31. DRUG DISCOVERY OUTSOURCING MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 32. DRUG DISCOVERY OUTSOURCING MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. DRUG DISCOVERY OUTSOURCING MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY SERVICE TYPE, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY SERVICE TYPE, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY BIOLOGICAL SERVICES, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY BIOLOGICAL SERVICES, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY BIOLOGICAL SERVICES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY BIOLOGICAL SERVICES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY BIOLOGICAL SERVICES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY BIOLOGICAL SERVICES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY BIOLOGICAL SERVICES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY BIOLOGICAL SERVICES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY ASSAY DEVELOPMENT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY ASSAY DEVELOPMENT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY ASSAY DEVELOPMENT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY ASSAY DEVELOPMENT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY ASSAY DEVELOPMENT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY ASSAY DEVELOPMENT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY BIOLOGICAL TESTING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY BIOLOGICAL TESTING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY BIOLOGICAL TESTING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY BIOLOGICAL TESTING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY BIOLOGICAL TESTING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY BIOLOGICAL TESTING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CHEMICAL SERVICES, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CHEMICAL SERVICES, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CHEMICAL SERVICES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CHEMICAL SERVICES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CHEMICAL SERVICES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CHEMICAL SERVICES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CHEMICAL SERVICES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CHEMICAL SERVICES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CUSTOM SYNTHESIS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CUSTOM SYNTHESIS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CUSTOM SYNTHESIS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CUSTOM SYNTHESIS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CUSTOM SYNTHESIS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CUSTOM SYNTHESIS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY PROCESS R&D, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY PROCESS R&D, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY PROCESS R&D, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY PROCESS R&D, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY PROCESS R&D, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY PROCESS R&D, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY DATA MANAGEMENT SERVICES, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY DATA MANAGEMENT SERVICES, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY DATA MANAGEMENT SERVICES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY DATA MANAGEMENT SERVICES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY DATA MANAGEMENT SERVICES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY DATA MANAGEMENT SERVICES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY DATA MANAGEMENT SERVICES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY DATA MANAGEMENT SERVICES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY BIOINFORMATICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY BIOINFORMATICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY BIOINFORMATICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY BIOINFORMATICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY BIOINFORMATICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY BIOINFORMATICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY DATA INTEGRATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY DATA INTEGRATION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY DATA INTEGRATION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY DATA INTEGRATION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY DATA INTEGRATION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY DATA INTEGRATION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY DISCOVERY PHASE, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY DISCOVERY PHASE, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY LEAD OPTIMIZATION, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY LEAD OPTIMIZATION, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY LEAD OPTIMIZATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY LEAD OPTIMIZATION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY LEAD OPTIMIZATION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY LEAD OPTIMIZATION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY LEAD OPTIMIZATION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY LEAD OPTIMIZATION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY COMPOUND SCREENING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY COMPOUND SCREENING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY COMPOUND SCREENING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY COMPOUND SCREENING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY COMPOUND SCREENING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY COMPOUND SCREENING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY STRUCTURE-BASED DRUG DESIGN, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY STRUCTURE-BASED DRUG DESIGN, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY STRUCTURE-BASED DRUG DESIGN, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY STRUCTURE-BASED DRUG DESIGN, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY STRUCTURE-BASED DRUG DESIGN, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY STRUCTURE-BASED DRUG DESIGN, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY TARGET IDENTIFICATION, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY TARGET IDENTIFICATION, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY TARGET IDENTIFICATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY TARGET IDENTIFICATION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY TARGET IDENTIFICATION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY TARGET IDENTIFICATION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY TARGET IDENTIFICATION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY TARGET IDENTIFICATION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY BIOMARKER DISCOVERY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY BIOMARKER DISCOVERY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY BIOMARKER DISCOVERY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY BIOMARKER DISCOVERY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY BIOMARKER DISCOVERY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY BIOMARKER DISCOVERY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY GENOMIC SEQUENCING METHODS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY GENOMIC SEQUENCING METHODS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY GENOMIC SEQUENCING METHODS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY GENOMIC SEQUENCING METHODS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY GENOMIC SEQUENCING METHODS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY GENOMIC SEQUENCING METHODS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY WORKFLOW, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY WORKFLOW, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY LEAD IDENTIFICATION & CANDIDATE OPTIMIZATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY LEAD IDENTIFICATION & CANDIDATE OPTIMIZATION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY LEAD IDENTIFICATION & CANDIDATE OPTIMIZATION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY LEAD IDENTIFICATION & CANDIDATE OPTIMIZATION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY LEAD IDENTIFICATION & CANDIDATE OPTIMIZATION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY LEAD IDENTIFICATION & CANDIDATE OPTIMIZATION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY PRECLINICAL DEVELOPMENT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY PRECLINICAL DEVELOPMENT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY PRECLINICAL DEVELOPMENT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY PRECLINICAL DEVELOPMENT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY PRECLINICAL DEVELOPMENT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY PRECLINICAL DEVELOPMENT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY TARGET IDENTIFICATION & SCREENING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY TARGET IDENTIFICATION & SCREENING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY TARGET IDENTIFICATION & SCREENING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY TARGET IDENTIFICATION & SCREENING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY TARGET IDENTIFICATION & SCREENING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY TARGET IDENTIFICATION & SCREENING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY TARGET VALIDATION & FUNCTIONAL INFORMATICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY TARGET VALIDATION & FUNCTIONAL INFORMATICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY TARGET VALIDATION & FUNCTIONAL INFORMATICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY TARGET VALIDATION & FUNCTIONAL INFORMATICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY TARGET VALIDATION & FUNCTIONAL INFORMATICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY TARGET VALIDATION & FUNCTIONAL INFORMATICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY DRUG TYPE, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY LARGE MOLECULES, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY LARGE MOLECULES, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY LARGE MOLECULES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY LARGE MOLECULES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY LARGE MOLECULES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY LARGE MOLECULES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY LARGE MOLECULES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY LARGE MOLECULES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY BIOLOGICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY BIOLOGICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY BIOLOGICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY BIOLOGICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY BIOLOGICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY BIOLOGICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 151. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY BIOSIMILLAR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 152. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY BIOSIMILLAR, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 153. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY BIOSIMILLAR, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 154. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY BIOSIMILLAR, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 155. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY BIOSIMILLAR, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 156. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY BIOSIMILLAR, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 157. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY SMALL MOLECULES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 158. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY SMALL MOLECULES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 159. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY SMALL MOLECULES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 160. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY SMALL MOLECULES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 161. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY SMALL MOLECULES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 162. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY SMALL MOLECULES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 163. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY APPLICATION AREA, 2018-2024 (USD MILLION)
  • TABLE 164. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY APPLICATION AREA, 2025-2032 (USD MILLION)
  • TABLE 165. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2018-2024 (USD MILLION)
  • TABLE 166. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2025-2032 (USD MILLION)
  • TABLE 167. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CARDIOVASCULAR DISEASES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 168. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CARDIOVASCULAR DISEASES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 169. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CARDIOVASCULAR DISEASES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 170. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CARDIOVASCULAR DISEASES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 171. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CARDIOVASCULAR DISEASES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 172. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CARDIOVASCULAR DISEASES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 173. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY HEART FAILURE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 174. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY HEART FAILURE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 175. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY HEART FAILURE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 176. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY HEART FAILURE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 177. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY HEART FAILURE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 178. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY HEART FAILURE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 179. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY HYPERTENSION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 180. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY HYPERTENSION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 181. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY HYPERTENSION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 182. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY HYPERTENSION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 183. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY HYPERTENSION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 184. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY HYPERTENSION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 185. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2024 (USD MILLION)
  • TABLE 186. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY INFECTIOUS DISEASES, 2025-2032 (USD MILLION)
  • TABLE 187. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 188. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 189. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY INFECTIOUS DISEASES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 190. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY INFECTIOUS DISEASES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 191. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY INFECTIOUS DISEASES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 192. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY INFECTIOUS DISEASES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 193. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY BACTERIAL INFECTIONS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 194. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY BACTERIAL INFECTIONS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 195. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY BACTERIAL INFECTIONS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 196. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY BACTERIAL INFECTIONS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 197. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY BACTERIAL INFECTIONS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 198. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY BACTERIAL INFECTIONS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 199. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY VIRAL INFECTIONS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 200. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY VIRAL INFECTIONS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 201. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY VIRAL INFECTIONS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 202. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY VIRAL INFECTIONS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 203. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY VIRAL INFECTIONS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 204. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY VIRAL INFECTIONS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 205. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY ONCOLOGY, 2018-2024 (USD MILLION)
  • TABLE 206. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY ONCOLOGY, 2025-2032 (USD MILLION)
  • TABLE 207. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 208. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY ONCOLOGY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 209. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY ONCOLOGY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 210. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY ONCOLOGY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 211. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY ONCOLOGY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 212. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY ONCOLOGY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 213. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY HEMATOLOGICAL MALIGNANCIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 214. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY HEMATOLOGICAL MALIGNANCIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 215. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY HEMATOLOGICAL MALIGNANCIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 216. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY HEMATOLOGICAL MALIGNANCIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 217. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY HEMATOLOGICAL MALIGNANCIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 218. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY HEMATOLOGICAL MALIGNANCIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 219. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY SOLID TUMORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 220. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY SOLID TUMORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 221. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY SOLID TUMORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 222. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY SOLID TUMORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 223. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY SOLID TUMORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 224. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY SOLID TUMORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 225. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 226. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 227. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, 2018-2024 (USD MILLION)
  • TABLE 228. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, 2025-2032 (USD MILLION)
  • TABLE 229. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 230. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 231. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 232. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 233. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 234. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 235. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY FULL-SERVICE CROS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 236. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY FULL-SERVICE CROS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 237. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY FULL-SERVICE CROS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 238. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY FULL-SERVICE CROS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 239. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY FULL-SERVICE CROS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 240. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY FULL-SERVICE CROS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 241. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY SPECIALTY CROS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 242. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY SPECIALTY CROS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 243. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY SPECIALTY CROS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 244. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY SPECIALTY CROS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 245. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY SPECIALTY CROS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 246. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY SPECIALTY CROS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 247. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, 2018-2024 (USD MILLION)
  • TABLE 248. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, 2025-2032 (USD MILLION)
  • TABLE 249. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 250. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 251. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 252. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 253. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 254. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 255. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY LARGE ENTERPRISES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 256. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY LARGE ENTERPRISES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 257. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY LARGE ENTERPRISES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 258. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY LARGE ENTERPRISES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 259. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY LARGE ENTERPRISES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 260. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY LARGE ENTERPRISES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 261. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY SMES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 262. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY SMES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 263. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY SMES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 264. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY SMES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 265. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY SMES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 266. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY SMES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 267. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2024 (USD MILLION)
  • TABLE 268. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY RESEARCH INSTITUTES, 2025-2032 (USD MILLION)
  • TABLE 269. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 270. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 271. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY RESEARCH INSTITUTES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 272. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY RESEARCH INSTITUTES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 273. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY RESEARCH INSTITUTES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 274. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY RESEARCH INSTITUTES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 275. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY ACADEMIC INSTITUTIONS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 276. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY ACADEMIC INSTITUTIONS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 277. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY ACADEMIC INSTITUTIONS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 278. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY ACADEMIC INSTITUTIONS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 279. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY ACADEMIC INSTITUTIONS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 280. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY ACADEMIC INSTITUTIONS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 281. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY GOVERNMENT RESEARCH CENTERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 282. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY GOVERNMENT RESEARCH CENTERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 283. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY GOVERNMENT RESEARCH CENTERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 284. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY GOVERNMENT RESEARCH CENTERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 285. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY GOVERNMENT RESEARCH CENTER